dofequidar has been researched along with fluorouracil in 1 studies
| Studies (dofequidar) | Trials (dofequidar) | Recent Studies (post-2010) (dofequidar) | Studies (fluorouracil) | Trials (fluorouracil) | Recent Studies (post-2010) (fluorouracil) |
|---|---|---|---|---|---|
| 40 | 2 | 5 | 45,562 | 9,307 | 14,663 |
| Protein | Taxonomy | dofequidar (IC50) | fluorouracil (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.32 | |
| Thymidylate synthase | Mus musculus (house mouse) | 1.58 | |
| Aromatase | Homo sapiens (human) | 0.63 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aogi, K; Asaga, T; Ikeda, T; Ito, Y; Kobayashi, T; Minami, H; Noguchi, S; Nomizu, T; Ohashi, Y; Saeki, T; Sato, W; Toi, M; Tsuruo, T; Yamamoto, N | 1 |
1 trial(s) available for dofequidar and fluorouracil
| Article | Year |
|---|---|
Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Double-Blind Method; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Quinolines; Treatment Outcome | 2007 |